Brief: MaaT Pharma FY Operating Loss Widens To EUR 9.0 Million

Maat Pharma SA

14/04/2022 07:28

April 14 (Reuters) - Maat Pharma SA  MAAT.PA :
    * AS OF DECEMBER 31, 2021, CASH AND CASH EQUIVALENTS WERE
€43.3
MILLION AND TURNOVER WAS €1.0 MILLION
    * FY OPERATING LOSS EUR 8.9 MILLION VERSUS LOSS EUR 5.3
MILLION
YEAR AGO
    * FY NET LOSS EUR 9.0 MILLION VERSUS LOSS EUR 5.3 MILLION
YEAR AGO
    * KEY MILESTONES TARGETED IN 2022: Q1 2022: EXPECTS TO
PUBLISH THE
FULL TOPLINE RESULTS OF THE PHASE 1B CLINICAL TRIAL OF MAAT033,
ITS SECOND DRUG CANDIDATE, PERFORMED IN PATIENTS WITH ACUTE
MYELOID LEUKEMIA
    * KEY MILESTONES TARGETED IN 2022: END SECOND SEMESTER: A
PIVOTAL
PHASE 2/3 MAY START TO EVALUATE MAAT033 AS A PROPHYLACTIC
TREATMENT IN PATIENTS WITH LIQUID TUMORS RECEIVING ALLO-HSCT

Source text for Eikon:  ID:nBw9bLxZXa 
Further company coverage:  MAAT.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))